BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mady R, Grover W, Butrus S. Ocular complications of inflammatory bowel disease. ScientificWorldJournal. 2015;2015:438402. [PMID: 25879056 DOI: 10.1155/2015/438402] [Cited by in Crossref: 22] [Cited by in F6Publishing: 13] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Cuny A, Guillo L, Baumann C, Netter P, Danese S, Caron B, Peyrin-biroulet L, Angioi K. Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era. JCM 2022;11:4538. [DOI: 10.3390/jcm11154538] [Reference Citation Analysis]
2 Hadji H, Bouchemal K. Advances in the treatment of inflammatory bowel disease: Focus on polysaccharide nanoparticulate drug delivery systems. Adv Drug Deliv Rev 2022;181:114101. [PMID: 34999122 DOI: 10.1016/j.addr.2021.114101] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
3 Ansari AS, Bertalot C, Mathews D, Mathews JP. Bilateral occlusive retinal vasculitis associated with primary sclerosing cholangitis. Saudi J Ophthalmol 2020;34:310-2. [PMID: 34527880 DOI: 10.4103/1319-4534.322598] [Reference Citation Analysis]
4 Shah J, Shah A, Hassman L, Gutierrez A. Ocular Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izaa359. [PMID: 33501989 DOI: 10.1093/ibd/izaa359] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
5 Yamamoto-Furusho JK, Sánchez-Morales GE. Factors Associated with the Presence of Extraintestinal Manifestations in Patients with Ulcerative Colitis in a Latin American Country. Inflamm Intest Dis 2020;5:200-4. [PMID: 33313072 DOI: 10.1159/000510070] [Reference Citation Analysis]
6 Sengul Samanci N, Poturoglu S, Samanci C, Ustabasioglu FE, Koldas M, Duman AE, Ormeci AC. The Relationship between Ocular Vascular Changes and the Levels of Malondialdehyde and Vascular Endothelial Growth Factor in Patients with Inflammatory Bowel Disease. Ocul Immunol Inflamm 2020;:1-5. [PMID: 32255700 DOI: 10.1080/09273948.2020.1740281] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Imam L, Haboubi HN. G-Eye: ocular manifestations of gastrointestinal disease. Frontline Gastroenterol 2020;11:162-7. [PMID: 32133116 DOI: 10.1136/flgastro-2018-101083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Biedermann L, Renz L, Fournier N, Rossel JB, Butter M, Bluemel S, Vavricka SR, Rogler G, Scharl M. Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. Therap Adv Gastroenterol 2019;12:1756284819865142. [PMID: 31447932 DOI: 10.1177/1756284819865142] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
9 Jin M, Wang Y, Yang X, Yin H, Nie S, Wu X. Structure characterization of a polysaccharide extracted from noni (Morinda citrifolia L.) and its protective effect against DSS-induced bowel disease in mice. Food Hydrocolloids 2019;90:189-97. [DOI: 10.1016/j.foodhyd.2018.11.049] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 10.3] [Reference Citation Analysis]
10 Xu F, Dahlhamer JM, Terlizzi EP, Wheaton AG, Croft JB. Receipt of Preventive Care Services Among US Adults with Inflammatory Bowel Disease, 2015–2016. Dig Dis Sci 2019;64:1798-808. [DOI: 10.1007/s10620-019-05494-w] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Barta Z, Czompa L, Rentka A, Zold E, Remenyik J, Biro A, Gesztelyi R, Zsuga J, Szodoray P, Kemeny-Beke A. Evaluation of Objective Signs and Subjective Symptoms of Dry Eye Disease in Patients with Inflammatory Bowel Disease. Biomed Res Int 2019;2019:8310583. [PMID: 30729131 DOI: 10.1155/2019/8310583] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
12 Lee DH, Han JY, Park JJ, Cheon JH, Kim M. Ophthalmologic Manifestation of Inflammatory Bowel Disease: A Review. Korean J Gastroenterol 2019;73:269. [DOI: 10.4166/kjg.2019.73.5.269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Walldorf J, Twarz M, Schober C, Michl P, Hammer T. High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center. Eur J Gastroenterol Hepatol 2018;30:1502-6. [PMID: 30148806 DOI: 10.1097/MEG.0000000000001248] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
14 Monaghan TM, Albanese G, Kaye P, Thomas JD, Abercrombie LC, Moran GW. Orbital Inflammatory Complications of Crohn's Disease: A Rare Case Series. Clin Med Insights Gastroenterol 2018;11:1179552218757512. [PMID: 29497344 DOI: 10.1177/1179552218757512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Fine S, Nee J, Thakuria P, Duff B, Farraye FA, Shah SA. Ocular, Auricular, and Oral Manifestations of Inflammatory Bowel Disease. Dig Dis Sci 2017;62:3269-79. [PMID: 29064013 DOI: 10.1007/s10620-017-4781-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
16 Troncoso LL, Biancardi AL, de Moraes Jr HV, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol 2017; 23(32): 5836-5848 [PMID: 28932076 DOI: 10.3748/wjg.v23.i32.5836] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 37] [Article Influence: 11.4] [Reference Citation Analysis]
17 Yang X, Gao XC, Liu J, Ren HY. Effect of EPEC endotoxin and bifidobacteria on intestinal barrier function through modulation of toll-like receptor 2 and toll-like receptor 4 expression in intestinal epithelial cell-18. World J Gastroenterol 2017; 23(26): 4744-4751 [PMID: 28765695 DOI: 10.3748/wjg.v23.i26.4744] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
18 Pandey N, Herrera HH, Johnson CM, MacCarthy AA, Copeland LA. Preventative care for patients with inflammatory bowel disease in the Veterans Health Administration. Medicine (Baltimore). 2016;95:e4012. [PMID: 27399081 DOI: 10.1097/md.0000000000004012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.2] [Reference Citation Analysis]
19 Gupta AS, Ortega-Loayza AG. Ocular pyoderma gangrenosum: A systematic review. J Am Acad Dermatol 2017;76:512-8. [PMID: 27836332 DOI: 10.1016/j.jaad.2016.08.049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
20 Siqueira RC, Kaiser Junior RL, Ruiz LP, Ruiz MA. Ischemic retinopathy associated with Crohn's disease. Int Med Case Rep J. 2016;9:197-200. [PMID: 27524921 DOI: 10.2147/imcrj.s108855] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]